Disease landscape

Leukemia clinical trials

Get alerts when Leukemia trials change

2,162 active trials 1,265 recruiting 191 Phase 3 687 sponsors 304 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 55 of 304 changes on 20 trials

2026-08-28
Recruitment suspended
Recruitment suspended: Unacceptable Toxicity
NCT03816319 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… · National Cancer Institute (NCI) · Phase 1
2026-08-20
Trial terminated
Trial terminated: Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug
Enrollment reduced: 10 → 4 participants
Primary completion moved earlier: 2028-12 → 2026-07-01
Completion moved earlier: 2028-12 → 2026-07-01
NCT07556757 A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic… · ImmunityBio, Inc. · Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2028-07-31 → 2026-07-01
Completion moved earlier: 2029-12-31 → 2026-07-31
NCT04010877 Multiple CAR-T Cell Therapy Targeting AML · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-27
Withdrawn before enrolling
Trial withdrawn: Strategic adjustment.
Enrollment reduced: 10 → 0 participants
Primary completion moved earlier: 2028-10-31 → 2026-03-30
Completion moved earlier: 2028-10-31 → 2026-03-30
NCT07338357 Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · First Affiliated Hospital of Guangxi Medical University · Early Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2029-12-31 → 2026-07-01
Completion moved earlier: 2030-12-31 → 2026-07-31
NCT05277753 NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL · Shenzhen Geno-Immune Medical Institute · Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2029-12-31 → 2026-07-01
Completion moved earlier: 2030-12-31 → 2026-07-31
NCT05262673 NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL · Shenzhen Geno-Immune Medical Institute · Phase 1
2026-08-22
Recruitment suspended
Recruitment suspended: Accrual goal met
NCT03728335 Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation · City of Hope Medical Center · Phase 2
2026-08-21
Trial terminated
Trial terminated: \<75% participants
Primary completion moved earlier: 2026-11-30 → 2026-08-14
Completion moved earlier: 2026-11-30 → 2026-08-14
NCT02392572 ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-14
Withdrawn before enrolling
Trial withdrawn: The trial has been stopped pending FDA approval of modifications to the trial protocol.
Enrollment reduced: 24 → 0 participants
NCT06703216 Pre-emptive Anakinra for Cytokine Event Reduction · Kevin McNerney · Phase 1/2
2026-08-07
Trial terminated
Trial terminated: The study was closed due to the end of funding.
NCT04994808 Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… · Fred Hutchinson Cancer Center · Phase 2
2026-08-06
Withdrawn before enrolling
Trial withdrawn: Lack of funding
Enrollment reduced: 100 → 0 participants
Trial sites reduced: 7 → 0 locations
NCT06903702 A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years… · Memorial Sloan Kettering Cancer Center · Phase 2
2026-08-11
Recruitment suspended
Recruitment suspended: Recruitment on hold with plans to open to accrual again soon.
NCT06492707 DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… · Fred Hutchinson Cancer Center · Phase 1
2026-08-21
Primary completion pushed: 2028-06-30 → 2028-12-31
Completion pushed: 2028-06-30 → 2028-12-31
NCT05579132 A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic… · MSD R&D (China) Co., Ltd. · Phase 1/2
2026-08-21
Primary completion pushed: 2027-09-16 → 2032-04-05
NCT02386800 CINC424A2X01B Rollover Protocol · Novartis Pharmaceuticals · Phase 4
2026-08-20
Primary completion pushed: 2026-11-13 → 2028-02-11
Primary endpoint(s) modified
Completion pushed: 2027-06-29 → 2028-09-15
Trial arms changed: 3 → 4
NCT06137118 AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia · AstraZeneca · Phase 1/2
2026-08-20
Primary completion pushed: 2029-05 → 2030-12
Enrollment reduced: 110 → 66 participants
Enrollment closed, study ongoing
Completion pushed: 2029-05 → 2030-12
NCT02966756 A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic… · AbbVie · Phase 2
2026-08-21
Primary completion pushed: 2026-08 → 2026-12
NCT06001788 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory… · Kura Oncology, Inc. · Phase 1
2026-07-30
Primary completion pushed: 2026-05 → 2029-08
Completion pushed: 2026-06 → 2029-08
NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… · Grifols Therapeutics LLC · Phase 3
2026-08-28
Primary completion pushed: 2028-09 → 2030-09
Completion pushed: 2028-09 → 2030-09
NCT05904106 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly… · Technische Universität Dresden · Phase 2
2026-08-18
Primary completion pushed: 2026-01-31 → 2026-12-31
NCT06927466 A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019… · Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-19 NCT07774390 Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL European Research Initiative on CLL new
2026-08-19 NCT07773909 Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive… Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh new Phase 4
2026-08-18 NCT07771803 A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia… Roger Strair new Early Phase 1
2026-08-17 NCT07766850 Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage… Christer C Nilsson new Phase 1/2
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new
2026-08-12 NCT07761533 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Chaser Therapeutics, Inc. new Phase 1/2
2026-08-10 NCT07755202 Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With… Florian Kuchenbauer new Phase 2
2026-08-07 NCT07751991 A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML Charm Therapeutics new Phase 1
2026-08-07 NCT07751783 Development and Dissemination of Exercise Prescription and Intervention for Cancer… Kaohsiung Medical University Chung-Ho Memorial Hospital new
2026-08-06 NCT07749976 GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL… Vitruviae new Phase 1/2

Active trials by phase

Early Phase 1
71
Phase 1
446
Phase 1/2
258
Phase 2
606
Phase 2/3
45
Phase 3
146
Phase 4
20
Not charted: 570 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 2,162

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07218341 A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… Eli Lilly and Company Recruiting 2026-08-21
NCT06651970 Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL… AstraZeneca Recruiting 2026-08-14
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in… AbbVie Recruiting 2026-08-14
NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Rigel Pharmaceuticals Recruiting 2026-08-11
NCT06289673 Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute… St. Jude Children's Research Hospital Recruiting 2026-07-14
NCT04877522 Asciminib Roll-over Study Novartis Pharmaceuticals Recruiting 2026-07-06
NCT06370000 Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML)… Virginia Commonwealth University Recruiting 2026-05-29
NCT07561892 Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating… Fujian Medical University Union Hospital Recruiting 2026-05-01
NCT06876649 A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Eli Lilly and Company Recruiting 2026-03-02
NCT06876662 A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic… Eli Lilly and Company Recruiting 2026-03-02
NCT07016165 Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in… Gadjah Mada University Recruiting 2025-08-22
NCT06918054 Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia Ain Shams University Recruiting 2025-04-09
NCT06571825 RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR He Huang Recruiting 2024-08-26
NCT06339775 Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation Suping ZHANG Recruiting 2024-04-01
NCT02386800 CINC424A2X01B Rollover Protocol Novartis Pharmaceuticals Active, Not Recruiting 2026-08-20
NCT07320534 Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During… Gadjah Mada University Not Yet Recruiting 2026-01-08
NCT03229200 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Pharmacyclics Switzerland GmbH Active, Not Recruiting 2025-10-30
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in… AbbVie Active, Not Recruiting 2025-08-12
NCT06918080 Hepatoprotective Measures for Children at High Risk of NAFLD Ain Shams University Active, Not Recruiting 2025-04-09
NCT04790045 Lymph Node Microenvironment Modifications in Patients With CLL Treated With… Paolo Ghia Not Yet Recruiting 2023-10-03
Phase 3
NCT04269902 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… National Cancer Institute (NCI) Recruiting 2026-08-27
NCT05947851 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line… Merck Sharp & Dohme LLC Recruiting 2026-08-27
NCT06136559 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib… Merck Sharp & Dohme LLC Recruiting 2026-08-27
NCT06973187 A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to… BeOne Medicines Recruiting 2026-08-26
NCT07504458 Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute… Quetzal Therapeutics Recruiting 2026-08-26
See all 2,162 active Leukemia trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (117) · National Cancer Institute (NCI) (89) · Institute of Hematology & Blood Diseases Hospital, China (65) · City of Hope Medical Center (57) · The First Affiliated Hospital of Soochow University (52) · Memorial Sloan Kettering Cancer Center (43) · Dana-Farber Cancer Institute (33) · Novartis Pharmaceuticals (25) · St. Jude Children's Research Hospital (25) · Children's Oncology Group (24)

Get alerts when Leukemia trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free